Not sure which service fits your situation?
Answer 4 quick questions and we'll highlight the best fit.
Step 1 of 4
What best describes your situation?
This tool helps you navigate our services. It is not a medical assessment.
Answer 4 quick questions and we'll highlight the best fit.
What best describes your situation?
This tool helps you navigate our services. It is not a medical assessment.
PDF in preparation
A sanitized demonstration PDF will be published after final redaction, watermarking, and sign-off. It will show the structure of the signed memo patients receive, without patient identifiers.
Independent, structured medical advisory for complex cancer cases, regenerative medicine evaluations, advanced biomarker and genomic interpretation, and clinical trial eligibility support — delivered remotely worldwide.
The goal is simple: more clarity, fewer unknowns, and a documented plan you can discuss calmly with your treating team.
This advisory service is designed for:
Two review paths, each built around a different clinical question. You can combine them if your case needs both.
Choose the path that matches the patient's main question first — you can always add the other review later.
Every review is delivered as a structured, evidence-based document you can share with your local team.
Structured case summary
Key medical concerns
Surgical decision review
Evidence-based interpretation
Questions for your treating team
Next-step considerations
The more complete your records, the more precise the review. Gather what you have — we will tell you if anything is missing.
Medical reports
Pathology report
Imaging summaries
Current treatment plan
Surgery or discharge notes
Patient or family questions
Complete the structured questionnaire
Upload full medical documentation
Confirm scope + secure payment
Review (typically 3–5 business days)
Receive signed advisory memo (PDF)
7-day clarification window
You and your local team remain in full control. The advisory memo is a structured tool to support your decisions, not replace them.
Refund amounts depend on the service and on when you cancel, and are applied automatically. The figures below show how much is refunded in each case.
Founding Phase Professional Rates — Limited Until 31 December 2026
During the international expansion phase, a limited professional rate is available for a limited intake and may be adjusted in the future.
Estimated turnaround: 48–72 hours
A structured entry-level advisory designed to provide clarity when uncertainty begins — before committing to a comprehensive review.
Not a full multidisciplinary review. This service is professional orientation to reduce uncertainty and define direction.
€240
Estimated turnaround: 3–5 business days
Integrated review of pathology reports, imaging (CT / MRI / PET), laboratory findings, and treatment protocols.
A patient with advanced or recurrent cancer facing multiple treatment options and needing a structured comparison of approaches based on current evidence.
Delivered as: A structured, signed advisory memo (PDF).
€145
Estimated turnaround: 3–5 business days
Structured interpretation of advanced laboratory panels, including immune, inflammatory, angiogenic and neuro-immune markers, genomic panels and molecular profiling, and clinical proteomics tests performed in licensed laboratories.
Modeled on international molecular tumor board practices, adapted to individual cases and local treating teams.
Includes: Signed memo, clinical context, and targeted questions for the treating team.
Optional add-on: Memo + Video Explanation — €210
A patient has received complex biomarker or genomic test results and needs contextualized interpretation to guide treatment decisions with the local oncology team.
€225
Estimated turnaround: 3–5 business days
Independent evaluation of post-surgical complications, unexpected treatment responses, drug tolerance concerns, and protocol modifications.
Delivered as: Structured review memo (PDF).
€240
Estimated turnaround: 3–5 business days
Independent evaluation of emerging and advanced therapeutic strategies, including regenerative medicine approaches, cellular and protein-based therapies (research / advanced-care pathways), gene-editing technologies in research or clinical trial contexts, and personalized immune modulation concepts.
Focus: Scientific plausibility, clinical coherence, risk/benefit considerations, and regulatory/trial pathway clarification.
No therapeutic claims. No promises. Safety-first evaluation only.
A patient considering a commercial regenerative therapy or advanced treatment protocol and needs an independent, evidence-based assessment before proceeding.
Simple, lower-cost options for document-based second opinions and video explanation.
€20
€50
€100
€150
Level 1 — Trial Screening
€195
Estimated turnaround: 3–5 business days
Targeted search + eligibility review + shortlist + gap list.
Level 2 — Trial-Ready Dossier Preparation
€425
Estimated turnaround: 5–7 business days
Structured dossier aligned with trial requirements + submission-ready package.
Note: Trial acceptance is determined solely by trial sites.
€900
Estimated turnaround: 3-month plan
For selected complex cases requiring deeper planning.
Includes: Integrated review + structured roadmap + follow-up framework.